期刊
NATURE REVIEWS CLINICAL ONCOLOGY
卷 15, 期 7, 页码 399-400出版社
NATURE PORTFOLIO
DOI: 10.1038/s41571-018-0030-2
关键词
-
类别
Drug regulators' acceptance of any statistically significant improvement shown in a single randomized trial and lofty drug prices has created a situation where it is now, hypothetically, profitable for a company to run a clinical trials portfolio of chemically inert compounds. While the current cancer drug pipeline is certainly superior to inert drugs, we must rethink market incentives to encourage transformational drug development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据